Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 535 of 6351
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell …
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Off-the-Shelf cell therapy takes aim at tough blood cancers
Disease control Not yet recruitingThis is a single-arm, open-label pilot study to evaluate the safety and efficacy of CD19-targeted allogenic CAR-T cells (19UCART) in patients with relapsed/refractory B-cell hematologic malignancies. 12 patients are planned to be enrolled in the dose-escalation trial. The primary…
Phase 1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill aims to wipe out rare urinary tract cancer without surgery
Disease control Recruiting nowA Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Phase 2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo targets advanced colorectal cancer in major trial
Disease control Recruiting nowThis is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation par…
Phase 1/2 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Hope for down syndrome: drug may stop Alzheimer's seizures
Prevention Recruiting nowThe purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease. Patients will be random…
Phase 3 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
New program aims to boost HIV prevention in black men
Prevention By invitation onlyThe goal of this clinical trial is to determine the efficacy of a client-center care coordination intervention (C4) in improving pre-exposure prophylaxis (PrEP) adherence in Black men who have sex with men (MSM). The main aims of the study are: 1. Determine the efficacy of C4 fo…
Sponsor: University of Maryland, Baltimore • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktail aims to wipe out Triple-Positive breast tumors before surgery
Disease control Not yet recruitingThis study is a prospective, multicenter, single-arm, exploratory study. A total of 90 patients with early/later-stage triple-positive breast cancer who were scheduled to receive neoadjuvant therapy were recruited. They received neoadjuvant treatment with trastuzumab, pertuzumab,…
Phase 2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Triple therapy aims to wipe out rectal tumors before surgery
Disease control Not yet recruitingThe biological effective dose of short-course radiotherapy is relatively lower compared to long-course radiotherapy, which may lead to an increased local recurrence rate in patients with mid to low rectal cancer who are at high risk of locally advanced disease due to insufficient…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a lung drug fix blood vessel damage in rare artery disease?
Disease control Not yet recruitingTakayasu arteritis is a severe vasculitis which could lead to significant disability and even death. While standard anti-inflammatory treatments can manage the systemic inflammation, they failed to stop a key driver of the disease: vascular fibrosis. This fibrosis could result in…
Phase 4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for advanced breast cancer? Triple-Drug combo tested after key therapy fails
Disease control Not yet recruitingThis study aims to explore the efficacy and safety of neratinib combined with fulvestrant and eribulin in the treatment of HR+/HER2+ advanced breast cancer after trastuzumab deruxtecan resistance. The treatment regimen of neratinib + fulvestrant + eribulin in this study is expect…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Robot surgeons take on strokes: a new hope for brain bleed patients?
Disease control Recruiting nowThis substudy is a prospective, multicenter, parallel-controlled, randomized controlled trial designed to evaluate whether robot-assisted endoscopic evacuation of large basal ganglia hematomas can improve patient outcomes compared with traditional surgical approaches such as smal…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to wipe out rectal cancer before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC. Participants will take: Induction: SHR-1701 combined with CAPOX for one cycle. Radiotherapy: Short-course radiotherapy (SCRT) (25Gy/5F). Consolidation: SHR-1701 com…
Phase 2 • Sponsor: Hong Qiu • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a pill replace the needle for anemia in diabetic kidney disease?
Disease control CompletedThis randomized controlled trial compared roxadustat with erythropoietin for the treatment of anaemia in patients with diabetic nephropathy and chronic kidney disease. A total of 64 patients aged 18 to 75 years were enrolled at the Department of Nephrology, Sheikh Zayed Hospital,…
Sponsor: Hanzla Arshad • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Tailored drug combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingHR+/HER2+ breast cancer belongs to a special type of tumor with dual-channel signal activation. However, in clinical treatment, the preferred approach is usually the inhibition of the HER2 signaling pathway. Therefore, the non-pCR rate after neoadjuvant therapy is relatively high…
Phase 2 • Sponsor: The First Affiliated Hospital of Bengbu Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingBreast cancer is the most common malignancy in women, with approximately 20% classified as HER2-positive. Anti-HER2 blockade (trastuzumab plus pertuzumab) combined with chemotherapy constitutes the standard neoadjuvant regimen; however, the pathological complete response (pCR) ra…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy could open door to liver transplants for more patients
Disease control Not yet recruitingThis is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for liver transplantation. The primary objective is to as…
Sponsor: Ningbo Medical Center Lihuili Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gut bacteria boosts immunotherapy for liver cancer?
Disease control Not yet recruitingOn the basis of previous studies, this study intends to explore the efficacy of preoperative oral administration of Lactobacillus reuteri (Lr) combined with preoperative neoadjuvant/conversion therapy in patients with primary resectable hepatocellular carcinoma (HCC). We hypothes…
Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail shows promise for rare blood cancer
Disease control Recruiting nowThis is a prospective, open-label, single-arm clinical trial evaluating a treatment strategy for previously untreated Mantle Cell Lymphoma (MCL). The study will enroll patients who have not received prior systemic therapy for MCL. All patients will receive the ZGR induction regim…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with SMA: experimental drug ARGX-119 enters Mid-Stage trial
Disease control Recruiting nowThis study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Plant-Based compound stop deadly clots in pancreatic cancer?
Disease control Recruiting nowThe aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Phase 3 • Sponsor: Quercis Pharma AG • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC